There are 6 papers on aging in Experimental animals: none in people yet, 1 in animals, 5 reviews.
6 papers study it13 findings
See all 6 papers on Experimental animals
- Animals1
Interventions
7Dietary restriction
uplifespan2
2 studies
Dietary restriction
uplifespan2
Dietary restriction extends lifespan in E. animals (compared with ad libitum feeding).
“delays aging and extends lifespan in experimental animals compared with a diet of ad libitum feeding (AL) control animals”
Reviewcompared with ad libitum feeding
Mechanisms underlying retardation of aging by dietary energy restriction
Pathology international
Dietary restriction extends lifespan in E. animals.
“food restriction increases mean life span.”
Review
Diet as a modulator of aging and longevity
Federation proceedings
GLP-1 receptor agonists
downinfarct volume1downinflammation1upmotor function1
1 study
GLP-1 receptor agonists
downinfarct volume1downinflammation1upmotor function1
GLP-1 receptor agonists decrease inflammation in E. animals (stroke and Parkinson's disease models).
“GLP-1 agonists decreased neuroinflammatory (TNF-α, IL-1b, IL-6), oxidative (ROS, 4-HNE), and apoptotic (increased Bcl-2, decreased Bax) markers.”
Reviewstroke and Parkinson's disease models
GLP-1 agonist and neuroprotection in Stroke and Parkinson's disease: A systematic review
Disease-a-month : DM
GLP-1 receptor agonists improve motor function in E. animals (Parkinson's disease models).
“there was a notable improvement in motor functions (P < 0.001)”
ReviewParkinson's disease models
GLP-1 agonist and neuroprotection in Stroke and Parkinson's disease: A systematic review
Disease-a-month : DM
GLP-1 receptor agonists decrease infarct volume in E. animals (middle cerebral artery occlusion stroke models) (15.4 % ± 1.3 % (liraglutide); 40 % reduction with linagliptin).
“with a significant decrease in infarct volume, such as 15.4 % ± 1.3 % (liraglutide) and 40 % reduction with linagliptin”
Reviewmiddle cerebral artery occlusion stroke models
GLP-1 agonist and neuroprotection in Stroke and Parkinson's disease: A systematic review
Disease-a-month : DM
Rikavit
downage-related changes in metabolic indices1upaverage and maximal lifespan1upresistance to hazardous effects and adaptive potentials1
1 study
Rikavit
downage-related changes in metabolic indices1upaverage and maximal lifespan1upresistance to hazardous effects and adaptive potentials1
Rikavit improves resistance to hazardous effects and adaptive potentials in E. animals (hypoxia, physical and medicamentous loads).
“increase the resistance of an aging organism to the hazardous effects (hypoxia, physical and medicamentous loads) and its adaptive potentials.”
Animalshypoxia, physical and medicamentous loads
Vestnik Akademii meditsinskikh nauk SSSR
Rikavit decreases age-related changes in metabolic indices in E. animals.
“normalization of the age-related changes in metabolic indices in experimental animals.”
Animals
Vestnik Akademii meditsinskikh nauk SSSR
Rikavit extends average and maximal lifespan in E. animals.
“Experimental trials have shown that this drug causes prolongation of the average and maximal life-span”
Animals
Vestnik Akademii meditsinskikh nauk SSSR
Senotherapy
downcancer1uplifespan1
1 study
Senotherapy
downcancer1uplifespan1
Senotherapy lowers the risk of cancer in E. animals.
“Senotherapy prolongs the life span and decreases the incidence of cancer in experimental animal models”
Review
Senotherapy, cancer, and aging
Journal of geriatric oncology
Senotherapy extends lifespan in E. animals.
“Senotherapy prolongs the life span and decreases the incidence of cancer in experimental animal models”
Review
Senotherapy, cancer, and aging
Journal of geriatric oncology
Androgens
downmetabolic functioning1
1 study
Androgens
downmetabolic functioning1
Androgens impair metabolic functioning in E. animals (androgen excess).
“In women and experimental animals of reproductive age, androgen excess can adversely affect metabolic functioning, appetite, and body weight regulation.”
Reviewandrogen excessfemales
International journal of molecular sciences
Fisetin
downcellular senescence1
1 study
Fisetin
downcellular senescence1
Fisetin decreases cellular senescence in aged experimental animals.
“Senolytic agents, such as Fisetin, selectively eliminate SnCs and delay, prevent, or alleviate multiple disorders in aged experimental animals”
Reviewin aged experimental animals
Fisetin for COVID-19 in skilled nursing facilities: Senolytic trials in the COVID era
Journal of the American Geriatrics Society
Melatonin
downneurodegenerative disease1
1 study
Melatonin
downneurodegenerative disease1
Melatonin decreases neurodegenerative disease in E. animals (chemically-induced).
“deferring the signs of chemically-induced neurodegenerative conditions in experimental animals, the data are remarkably strong”
Reviewchemically-induced
Melatonin, longevity and health in the aged: an assessment
Free radical research